Investing
Eli Lilly’s head of diabetes and obesity unit to retire
© Reuters. FILE PHOTO: Eli Lilly logo is shown on one of the company’s offices in San Diego, California, U.S., September 17, 2020. REUTERS/Mike Blake/File Photo
(Reuters) -Eli Lilly and Co said on Wednesday that the head of its diabetes and obesity division, Mike Mason, will retire by the end of the year after more than three decades with the drugmaker.
Mason oversaw the late-stage development of tirzepatide, Lilly’s potential blockbuster that is sold under the brand name Mounjaro for diabetes and is under U.S. regulatory review for obesity.
Lilly said Patrik Jonsson, president of Lilly USA, will take over Mason’s role.
The company’s shares were down 1% in premarket trading.
Read the full article here
-
Investing6 days ago
Bank regulator gives BlackRock new deadline on bank stakes, Bloomberg reports By Reuters
-
Side Hustles5 days ago
How to Craft Marketing Campaigns That Reach Multiple Generations
-
Side Hustles5 days ago
LA Rental Prices Skyrocketing Despite Price Gouging Laws
-
Side Hustles6 days ago
Former Zillow Execs Target $1.3T Market
-
Side Hustles3 days ago
What to Do If TikTok is Banned — How to Protect Your Brand
-
Side Hustles7 days ago
FileJump Offers 2TB of Cloud Storage for $70—With No Strings Attached
-
Side Hustles2 days ago
Why the Best CEOs Think Like Anthropologists
-
Side Hustles7 days ago
5 AI Books Top Entrepreneurs Are Reading in a Rush for 2025